Ewgeni Jakubovski1, Anjali L Varigonda1, Nicholas Freemantle1, Matthew J Taylor1, Michael H Bloch1. 1. From the Yale Child Study Center, New Haven, Conn.; the University of Vermont College of Medicine, Burlington, Vt.; Child Study Center and Department of Psychiatry, Yale University, New Haven, Conn.; the Department of Primary Care and Population Health, University College London; and the Department of Psychosis Studies, King's College London.
Abstract
OBJECTIVE: Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder. METHOD: The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRIs for treating adults with major depressive disorder. Trials were also required to assess improvement in depression severity at multiple time points. Additional data were collected on treatment response and all-cause and side effect-related discontinuation. All medication doses were transformed into imipramine-equivalent doses. The longitudinal data were analyzed with a mixed-regression model. Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder. RESULTS: Forty studies involving 10,039 participants were included. Longitudinal modeling (dose-by-time interaction=0.0007, 95% CI=0.0001-0.0013) and endpoint analysis (meta-regression: β=0.00053, 95% CI=0.00018-0.00088, z=2.98) demonstrated a small but statistically significant positive association between SSRI dose and efficacy. Higher doses of SSRIs were associated with an increased likelihood of dropouts due to side effects (meta-regression: β=0.00207, 95% CI=0.00071-0.00342, z=2.98) and decreased likelihood of all-cause dropout (meta-regression: β=-0.00093, 95% CI=-0.00165 to -0.00021, z=-2.54). CONCLUSIONS: Higher doses of SSRIs appear slightly more effective in major depressive disorder. This benefit appears to plateau at around 250 mg of imipramine equivalents (50 mg of fluoxetine). The slightly increased benefits of SSRIs at higher doses are somewhat offset by decreased tolerability at high doses.
OBJECTIVE: Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder. METHOD: The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRIs for treating adults with major depressive disorder. Trials were also required to assess improvement in depression severity at multiple time points. Additional data were collected on treatment response and all-cause and side effect-related discontinuation. All medication doses were transformed into imipramine-equivalent doses. The longitudinal data were analyzed with a mixed-regression model. Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder. RESULTS: Forty studies involving 10,039 participants were included. Longitudinal modeling (dose-by-time interaction=0.0007, 95% CI=0.0001-0.0013) and endpoint analysis (meta-regression: β=0.00053, 95% CI=0.00018-0.00088, z=2.98) demonstrated a small but statistically significant positive association between SSRI dose and efficacy. Higher doses of SSRIs were associated with an increased likelihood of dropouts due to side effects (meta-regression: β=0.00207, 95% CI=0.00071-0.00342, z=2.98) and decreased likelihood of all-cause dropout (meta-regression: β=-0.00093, 95% CI=-0.00165 to -0.00021, z=-2.54). CONCLUSIONS: Higher doses of SSRIs appear slightly more effective in major depressive disorder. This benefit appears to plateau at around 250 mg of imipramine equivalents (50 mg of fluoxetine). The slightly increased benefits of SSRIs at higher doses are somewhat offset by decreased tolerability at high doses.
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters Journal: Arch Gen Psychiatry Date: 2005-06
Authors: Michael J Detke; Curtis G Wiltse; Craig H Mallinckrodt; Robert K McNamara; Mark A Demitrack; Istvan Bitter Journal: Eur Neuropsychopharmacol Date: 2004-12 Impact factor: 4.600
Authors: L F Fabre; F S Abuzzahab; M Amin; J L Claghorn; J Mendels; W M Petrie; S Dubé; J G Small Journal: Biol Psychiatry Date: 1995-11-01 Impact factor: 13.382
Authors: Mar Carceller-Sindreu; Javier de Diego-Adeliño; Maria J Portella; Xavier Garcia-Moll; Maria Figueras; Aina Fernandez-Vidal; Josep M Queraltó; Dolors Puigdemont; Enric Álvarez Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-01-23 Impact factor: 5.270
Authors: Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch Journal: J Child Psychol Psychiatry Date: 2020-02-04 Impact factor: 8.982
Authors: Alexandra K Brooks; Tiffany M Janda; Marcus A Lawson; Jennifer L Rytych; Robin A Smith; Cecilia Ocampo-Solis; Robert H McCusker Journal: Brain Behav Immun Date: 2017-02-16 Impact factor: 7.217
Authors: Robert M Carney; Kenneth E Freedland; Eugene H Rubin; Michael W Rich; Brian C Steinmeyer; William S Harris Journal: J Clin Psychiatry Date: 2019-06-04 Impact factor: 4.384
Authors: Brian A Fallon; David K Ahern; Martina Pavlicova; Iordan Slavov; Natalia Skritskya; Arthur J Barsky Journal: Am J Psychiatry Date: 2017-06-29 Impact factor: 18.112
Authors: Jeffrey R Strawn; Jeffrey A Mills; Beau A Sauley; Jeffrey A Welge Journal: J Am Acad Child Adolesc Psychiatry Date: 2018-02-08 Impact factor: 8.829